Thymidylate synthase Monoklonaler Antikörper

• Featured Product
• KD/KO Validated

Thymidylate synthase Monoklonal Antikörper für WB

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human

Anwendung

WB

Konjugation

HRP

CloneNo.

1F5B7

Kat-Nr. : HRP-66725

Synonyme

TYMS, 1F5B7, DKCD, EC:2.1.1.45, HsT422

---

• 

  WB analysis of Jurkat using HRP-66725

  Jurkat cells were subjected to SDS PAGE followed by western blot with HRP-66725 (Thymidylate synthase antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Jurkat-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:20000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

HRP-66725 bindet in WB Thymidylate synthase und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: Thymidylate synthase fusion protein Ag7027
• Vollständiger Name: thymidylate synthetase
• Berechnetes Molekulargewicht: 36 kDa
• Beobachtetes Molekulargewicht: 36 kDa
• GenBank-Zugangsnummer: BC002567
• Gene symbol: TYMS
• Gene ID (NCBI): 7298
• Konjugation: HRP
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Thymidylate synthase gene (TYMS) encodes thymidylate synthase (TS) which is an important factor in the growth of tumor cells. TS can catalyze the transformation of intracellular uridine monophosphate (dump) into dTMP which is required for DNA replication and repairing. TS is a key enzyme in the process of cell proliferation, also is the important target enzymes of 5-FU and other chemotherapy drugs. The expression of TYMS is negatively correlated with the efficacy of chemotherapy and the prognosis of patients who suffer from rectal cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, esophageal cancer, pancreatic cancer and so on.